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Abstract
Background: The mast cell is a crucial effector cell in allergic rhinitis and other inflammatory diseases.
During the acute allergic reaction preformed mediators such as histamine, but also de novo produced
mediators such as leukotrienes (LTC4/D4/E4) and prostaglandins (PGD2) are released. Mast cells represent
targets for therapeutic intervention, and thus a human ex-vivo model to stimulate mast cells taken from
mucosal sites would be instrumental for drug intervention studies. We have aimed to activate mast cells
within ex-vivo human nasal tissue by IgE/anti-IgE specific (ε chain specific) stimulations and in this respect
to test the usability of nasal polyps versus inferior turbinates
Methods: Biopsy samples were collected from patients with nasal polyps and inferior turbinates from
patients who underwent sinus or septal surgery. Tissue fragments were primed with IgE 1 μg/ml for 60
minutes and then stimulated for 30 minutes with tissue culture medium (negative control), anti-IgE 10 μg/
ml, anti-IgE 30 μg/ml and ionomycin 10 μM (positive control). Histamine, leukotrienes and PGD2 were
measured in supernatants. To help provide an understanding of the extent of the response, the number
of tryptase and FcεRIα positive cells was evaluated by means of immunohistochemistry and the FcεRIα-
chain was measured by means of quantitative PCR in the nasal polyp and inferior turbinate tissues. Finally,
the correlation between IgE concentrations in the nasal tissue and the release of mediators was analysed.
Results:  Stimulations with anti-IgE on IgE-primed nasal tissue fragments lead to a concentration-
dependent release of histamine, leukotrienes and PGD2. The release of these early phase mediators was
significantly higher in nasal polyps compared to inferior turbinates, although tryptase, FcεRIα positive cells
and FcεRIα-chain transcripts were equally present in both groups. No correlation was found between
baseline concentrations of IgE, and the release of histamine, LTC4/LTD4/LTE4 and PGD2 after stimulation.
Conclusion: This human nasal challenge model mimics the allergic early phase reaction. The release of
histamine, cys-leukotrienes and PGD2 was significantly higher in nasal polyps versus inferior turbinates,
however, this observation could not be explained by differences in mast cell or FcεRI+ cell numbers.
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Background
Mast cells play a crucial role in allergic rhinitis and other
inflammatory responses. Positioned at mucosal surfaces,
these cells are situated to be among the first to encounter
antigens that elicit allergic reactions. Interaction of multi-
valent allergens with cell-bound specific immunoglob-
uline E (IgE) leads to cross-linking of the high affinity IgE
receptor (FcεRI), which is primarily expressed on mast
cells and basophils. First, this results in the immediate
release of the content of mast cell secretory granules,
which includes preformed mediators such as histamine,
neutral proteases and proteoglycans and second, it results
in the de novo synthesis of mediators including the prod-
ucts of the arachidonic acid metabolism, such as prostag-
landin D2 (PGD2) and sulfidopeptidyl leukotrienes C4/
D4/E4, and the production of several cytokines (i.e. IL-4,
IL-5, IL-6, TNF-α, IL-13) [1,2]. During the acute allergic
reaction mainly preformed mediators such as histamine,
but also newly produced mediators such as leukotrienes
(LTC4/D4/E4) and PGD2 are released [3]. These mediators
initiate rapid vascular permeability, leading to plasma
extravasation and tissue edema, mucous overproduction
and leukocyte recruitment.
Most early studies of mast cells rely on the use of trans-
formed mast cells from murine mastocytoma cells [4,5].
Currently, it is possible to grow human mast cells in vitro.
Interleukin (IL)-3, IL-6 and stem cell factor (SCF) may act
on hematopoietic stem cells present in bone marrow,
umbilical cord blood, fetal liver or peripheral blood and
make it possible to grow large numbers of committed
mast cell precursors. These cells express high levels of c-kit
receptor and FcεRI [6]. Furthermore, several mast cell
lines such as HMC-1 [7] or LAD-1/2 [8] are available to
study mast cell biology. The use of murine cells, the addi-
tion of several factors to grow human mast cells, or the use
of human mast cell lines may induce responses different
from primary in vivo tissue mast cells.
Considerable difficulties exist to isolate and stimulate
mast cells from nasal tissue; especially the limited amount
of tissue extracted after surgery (turbinotomy) and the low
number of mast cells isolated from nasal tissue, may give
problems to stimulate nasal mast cells directly [9]. To
study nasal mast cells, stimulations have been done in
enzymatic dispersed nasal polyp tissue [10,11]. Accessi-
bility of nasal polyp tissue allows for easy assessment of
interaction between different cell types in an inflamma-
tory environment; however, enzymatic digestion of tissue
may possible damage receptors and the comparability of
results obtained from nasal polyp stimulations to inferior
turbinate stimulations is not clear.
We therefore aimed to study mast cells and basophils in
their tissue environment by using IgE/anti-IgE driven (ε
chain specific) stimulations in human nasal tissue
explants without enzymatic digestion to closely mimic the
in vivo situation. Second we wanted to test the usability of
nasal polyps versus inferior turbinates in this respect, as
polyp tissue is easier to obtain in larger quantities. Finally,
we aimed to explain differences in the response between
tissues, and studied tryptase and FcεRIα + cell numbers, as




Nasal tissue was obtained from 8 polyp patients and 8
control patients at the Department of Otorhinolaryngol-
ogy of the University Hospital of Ghent. The ethical com-
mittee of the Ghent University Hospital approved the
study and all patients gave their written informed consent
prior to inclusion in the study.
None of the subjects received intranasal corticosteroids,
anti-histamines or anti-leukotrienes, oral and intranasal
decongestants or intranasal anticholinergics within 1
week prior to surgery and none of the subjects received
oral and/or intramuscular corticosteroids within 4 weeks
prior to surgery. For female subjects pregnancy or lacta-
tion was excluded.
The control group was composed of samples collected
from the inferior turbinates from patients undergoing sep-
tal surgery and/or turbinotomy because of nasal obstruc-
tion, unrelated to this study.
Nasal polyp samples were collected during functional
endoscopic sinus surgery. Nasal polyposis was diagnosed
based on symptoms, clinical examination, nasal endos-
copy, and sinus computed tomography (CT) scan accord-
ing to the EP3OS guidelines [13].
The atopic status of all patients was evaluated by skin
prick tests with a standard panel of 14 inhalant allergens,
including negative (NaCl solution) and positive controls
(10 mg/ml histamine solution). The reaction to a skin
prick test was considered positive if the wheal area caused
by the allergen was greater than 7 mm2 (diameter >3
mm). Patient characteristics are displayed in table 1.
The nasal tissue collected during surgery was immediately
transported to the laboratory, partly snap frozen in liquid
nitrogen, and stored at -80°C until analysis for immuno-
histochemistry, IgE measurement and PCR. The remain-
ing tissue was used for the ex-vivo stimulations.Journal of Inflammation 2009, 6:11 http://www.journal-inflammation.com/content/6/1/11
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Mechanical disruption and stimulations of human nasal 
tissue
The human nasal mucosa and submucosa was cut thor-
oughly in tissue culture medium consisting of RPMI 1640
(Sigma-Aldrich, Bornem, Belgium), containing 2 mM L-
Glutamine (Invitrogen, Merelbeke, Belgium), antibiotics
(50 IU/ml penicillin and 50 μg/ml streptomycin) (Invit-
rogen) and 0.1% BSA (Bovine Serum Albumin, Sigma).
The tissue was passed through a mesh to achieve compa-
rable fragments. The tissue fragments (+/- 0.9 mm3) were
weighed and resuspended as 0.04 g tissue/1 ml tissue cul-
ture medium. The tissue was preincubated for 1 hour at
37°C, 5% CO2 with 1 μg/ml human myeloma IgE (Calbi-
ochem, VWR International, Leuven, Belgium). After 3
washing steps the tissue fragments were resuspended in
the appropriate amount of culture medium and 0.5 ml of
this fragment suspension was dispensed per well of a 48
well plate. (BD Falcon, VWR, Leuven, Belgium). The frag-
ment suspensions were stimulated with either culture
medium (negative control), ε-chain specific anti-human
IgE antibody (Dako Belgium N.V., Heverlee, Belgium), at
10 or 30 μg/ml (Dako Belgium N.V., Heverlee, Belgium),
or 10 μM ionomycin (Calbiochem) for 30 minutes.
Supernatants were separated by centrifugation and stored
immediately at -20°C until analysis of histamine, LTC4/
D4/E4 and PGD2.
Measurements of mediators in supernatants of stimulated 
tissue fragments
Concentrations of histamine, LTC4/D4/E4 and PGD2 were
measured in tissue supernatants obtained after the stimu-
lations using ELISA kits for Histamine (IBL Hamburg,
Germany), LTC4/D4/E4  (Oxford Biomedical Research,
Nuclilab BV, Ede, The Netherlands) and PGD2 (Cayman
Chemicals, Ann Arbor, Michigan) following the instruc-
tions of the manufacture.
Immunohistochemistry
Cryostat sections were prepared (6 μm) and mounted on
SuperFrost Plus glass slides (Menzel Glaeser, Braunsch-
weig, Germany), packed in aluminium paper and stored
at -30°C until staining. Sections were immunohistochem-
ically stained with the following antibodies: mouse anti
human mast cell tryptase (clone G3, Chemicon Interna-
tional, Biognost, Heule, Belgium) and mouse anti human
FcεRIα (clone CRA1, Gentaur, Brussels, Belgium). For
immunohistochemical staining, specimens were fixed in
Carnoy's Fluid (60% ethanol, 30% chloroform, 10% gla-
cial acetic acid). Endogenous peroxidase activity was
blocked with 0.3% hydrogen peroxide in TBS (Tris-buff-
ered-Saline) containing 0.1% sodium azide for 20 min-
utes. The primary antibody or the negative control,
consisting of the corresponding isotype control, was incu-
bated for 1 hour and signal was detected using the LSAB+
technique conjugated with peroxidase according to the
manufacturer's instructions (labelled streptavidin-biotin;
Dako). The peroxidase activity was detected using AEC
Substrate chromogen (Dako), which results in a red-
stained precipitate. Finally the sections were counter-
stained with hematoxylin and mounted.
The number of positive cells was analysed using a magni-
fication of 400× and scored by two independent observers
who did not know the diagnosis and clinical data. The
analyses included 10 relevant fields of the biopsy, and for
each sample, the sum of positive cells/10 fields were
scored.
RNA preparation and real-time RT-PCR
Snap frozen tissue samples were placed in liquid nitrogen
and thoroughly ground with a mortar and pestle and
homogenized with Lysis Buffer (Bio-Rad Laboratories,
CA, USA). Total RNA was purified using the Aurum™ Total
RNA Mini Kit (Bio-Rad Laboratories, CA, USA) following
manufacture's intructions. One microgram of total RNA
was than reverse transcribed to generate cDNA with the
iScript cDNA Synthesis Kit (Bio-Rad Laboratories, CA,
USA) as instructed by the supplier. Expression of the
IgERα-chain was determined using real-time PCR per-
formed on an iCycler Real Time Detection System (Bio-
Rad Laboratories, CA, USA). Primers and probes were pur-
chased from Invitrogen (Merelbeke, Belgium) and con-
tained the following sequences: IgERα (sense): 5'-
TCTTCAGTGACTGGCTGCTCC-3', IgERα (antisense): 5'-
GCTGGCCCTCCATCACC-3', IgERα-probe: FAM-5'-
TCAGGCCTCTGCTGAG-3'-TAMRA [14]. PCR reaction
contained 20 ng of cDNA, 300 nM of specific primers, 100
nM of TaqMan probe and 1× TaqMan Master mix (Bio-
Rad Laboratories, CA, USA) in a final volume of 0.02 ml.
Amplification program consisted in 1 cycle at 95°C for 10
min followed by 40 cycles at 60°C for 1 min and 95°C for
15 seconds. The expression of two housekeeping genes:
Table 1: Patient characteristics
Inferior turbinates Nasal polyps
N8 8
Age (median, range) 36.5 (17–47) 38.5 (18–54)
Female/male 2/6 4/4
Asthma in history 1/8 0/8
Skin prick test-positive 0/8 2/8
Aspirin intolerance 0/8 0/8
Smoking 1/8 1/8Journal of Inflammation 2009, 6:11 http://www.journal-inflammation.com/content/6/1/11
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Beta actin (ACTB) and Hydroxymethyl-bilane synthase
(HMBS) was used to normalize for transcription and
amplification variations among samples after a validation
using the geNorm software as described previously [15].
The relative expression of the receptor was calculated with
the qBase program (version 1.3.5, UGent, Belgium) based
on the delta-CT relative quantification method. Results are
shown as relative expression units per 20 ng cDNA (RNA
based).
Measurement of IgE in tissue homogenates
Snap frozen tissue specimens were weighed, and 1 ml of
0.9% NaCl solution was added per every 0.1 g tissue. The
tissue was then homogenized with a mechanical homog-
enizer (B. Braun, Melsungen, Germany) at 1000 rpm for 5
min on ice as described previously [16]. After homogeni-
zation, the suspension was centrifuged at 3000 rpm for 10
min at 4°C and the supernatants separated and stored at -
80°C until analysis. Immunoglobuline E was measured
by the UNICAP system (Phadia, Uppsala, Sweden).
Statistical analysis
Statistical analysis was performed using the Wilcoxon test
(for paired comparisons). The Mann-Whitney U test was
used for between-group (unpaired) comparisons. P values
of less than .05 were considered as statistically significant.
Correlations were made by using the Spearman rank cor-
relation analysis.
Results
Mediator release after ex-vivo stimulations
A stimulation model was set up to stimulate inferior tur-
binate tissue (n = 8) and in larger quantities obtainable
nasal polyp tissue (n = 8). IgE-primed nasal tissue frag-
ments were stimulated with anti-IgE (10 μg/ml and 30 μg/
ml) or ionomycin (10 μM) for 30 minutes. Stimulation
resulted in a significant release and production of hista-
mine, leukotrienes and PGD2 measured in the superna-
tants by ELISA. These mediators were released in a
concentration-dependent manner, except for LTC4/D4/E4
in the inferior turbinate group (Table 2), where the differ-
ence between 10 and 30 μg/ml was not statistically signif-
icant.
After 30 minutes culture in medium alone, the spontane-
ous release of histamine and leukotrienes was signifi-
cantly higher in nasal polyps compared to inferior
turbinates (p < 0.01 and p = 0.03 respectively). However,
the spontaneous release of PGD2  was not different
between the two groups (p = 0.1). After correction for
spontaneous release, the induced release of histamine,
LTC4/D4/E4 and PGD2 was significantly higher in the nasal
polyp group compared to the inferior turbinate group,
both after stimulation with anti-IgE 10 μg/ml and anti-IgE
30 μg/ml (Fig 1).
Immunohistochemistry
In an attempt to explain the stronger response upon stim-
ulation in nasal polyps versus inferior turbinates, mast
cells and basophils were stained for tryptase and counted
(Fig 2A), but no difference in the total numbers of mast
cells in the nasal polyp group compared to the inferior
turbinate group was detected. Furthermore, staining for
FcεRIα showed no differences between the numbers of
positive cells in both groups (Fig 2B). Representative
stainings are shown in Fig 3.
FcεRIα-chain mRNA
To study the expression of the high affinity IgE receptor,
the amount of FcεRIα mRNA was quantified by RT-PCR in
the nasal polyp and inferior turbinate groups. Equivalent
FcεRIα mRNA levels were found in nasal polyps com-
pared to inferior turbinates (Fig 2C).
IgE in tissue homogenates
As it is described that the concentration of IgE is
related[12] to the surface expression of FcεRI, and IgE con-
centrations are significantly higher in nasal polyps com-
pared to controls [17], we studied the correlation between
the IgE levels in tissue homogenates, and the release of
histamine, LTC4/LTD4/LTE4 and PGD2 after anti-IgE chal-
lenge. Confirming earlier results, the concentrations of IgE
were significantly higher in nasal polyps [97.6 (55.3–
190.1) kUA/l] [median (IQR)] compared to inferior tur-
binates [10.3 (9.4–30.7) kUA/l] (p = 0.02). However, we
were not able to demonstrate any correlation between the
concentrations of IgE in nasal polyp homogenates and the
amount of histamine release (r = 0.05, p = 0.9) (r = 0.1, p
= 0.8), leukotriene release (r = 0.3, p = 0.4) (r = 0.4, p =
0.3) and PGD2 release (r = 0.3, p = 0.4) (r = 0.2, p = 0.5)
after anti-IgE 10 μg/ml and anti-IgE 30 μg/ml stimulation
respectively. Furthermore no correlation could be found
between the concentrations of IgE in inferior turbinate
homogenates and the amount of histamine release (r =
0.1, p = 0.7) (r = 0.5, p = 0.2), leukotriene release (r = 0.01,
p = 1.0) (r = 0.5, p = 0.2) and PGD2 release (r = 0.02, p =
1.0) (r = 0.8, p = 0.1) after anti-IgE 10 μg/ml and anti-IgE
30 μg/ml stimulation respectively.
Discussion
Until recently, cell systems used for exploration of mast
cell biology have mainly been of rodent origin (the rat
basophilic leukaemia cell line RBL-2H3, mouse bone
marrow derived mast cells). The only human cell line
available (HMC-1) [7] has been of limited usefulness due
to the cells' stem cell factor independence, and inconsist-
ent degranulation to IgE-dependent signals, presumably
due to variable expression of the FcεRIα-subunit [7,18].
Other cell cultures, designated LAD 1 and 2, derived from
bone marrow aspirates from a patient with mast cell sar-
coma/leukemia, resemble CD34+-derived human mastJournal of Inflammation 2009, 6:11 http://www.journal-inflammation.com/content/6/1/11
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cells with functional FcεRI and Fcγ RI receptors [8]. The
use of bone marrow derived mast cells [19], umbilical
cord blood derived mast cells [20], and foetal liver [21] or
peripheral blood derived mast cells [19] have improved
the models for studying mast cell biology [22]. Here, addi-
tion of certain interleukins such as IL-3, IL-6 or SCF to
CD34+ progenitor cells made it possible to grow large
numbers of committed mast cell precursors. However,
mast cells display phenotypic heterogeneity depending on
their tissue localisation, and any of those surrogate cell
systems may prove not to represent the mast cells in a dis-
eased tissue. It is therefore advantageous to study mast
cells derived from human nasal mucosal, especially dis-
eased tissue.
Pawankar et al [9] were able to isolate mast cells from
inferior turbinates and study the IgE receptor, however,
the number of mast cells remaining after stimulation is
too little to perform meaningful mast cell activation and
mediator release. Several studies [10,11] have made use of
mast cells within digested nasal polyp tissue for stimula-
tion, however these cells did not release histamine upon
IgE receptor stimulation [23].
In this study we stimulated ex-vivo nasal tissue with anti-
IgE to study mast cell activation and to compare the
response in inferior turbinates and nasal polyps. By using
whole tissue preparations, the cells remained in their nat-
ural environment, and unchanged surface receptor expres-
Table 2: Overview of anti-IgE and ionomycin-induced release of histamine (ng/ml), LTC4/LTD4/LTE4 (ng/ml) and PGD2 (pg/ml) after 30 
minutes in the nasal polyp (n = 8) and inferior turbinate group (n = 8). 
Histamine (ng/ml LTC4/LTD4/LTE4 (ng/ml) PGD2 (pg/ml)
Nasal polyps
RPMI 24.1 (15.1–32.6) 0.0815 (0.048–0.11) 109 (66.5–221)
Versus P < 0.01 P < 0.01 P < 0.01
Anti-igE 10 μg/ml 43.2 (28.1–55.5) 0.469 (0.348–0.816) 1960 (1518–4544)
Versus P < 0.01 P < 0.01 P < 0.01
Anti-IgE 30 μg/ml 63.6 (44.8–75.5) 0.675 (0.561–1.21) 4949 (2991–6152)
Ionomycin 10 μM 130 (77.5–135) 3.40 (1.80–5.37) 2717 (1364–4298)
Versus baseline P < 0.01 P < 0.01 P < 0.01
Inferior turbinates
RPMI 8.5 (5.6–12.9) 0.036 (0.016–0.0395) 58.6 (40.2–88.2)
Versus P < 0.01 P < 0.01 P < 0.01
Anti-igE 10 μg/ml 16.2 (12.0–20.2) 0.0655 (0.038–0.181) 840 (492–1269)
Versus P < 0.05 P = 0.44 P < 0.05
Anti-IgE 30 μg/ml (n = 6) 28.1 (21.8–31.7) 0.0715 (0.058–0.331) 1669 (1311–1732)
Ionomycin 10 μM 27.6 (22.3–45.5) 0.361(0.24–0.525) 967 (548–1373)
Versus baseline P < 0.01 P < 0.01 P < 0.01
Statistical analysis; Wilcoxon-test
Data are expressed as median +/- IQR.Journal of Inflammation 2009, 6:11 http://www.journal-inflammation.com/content/6/1/11
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sion was maintained by omitting enzymatic digestion,
thus closely mimicking the in vivo situation.
The stimulation with anti-IgE 10 μg/ml and anti-IgE 30
μg/ml resulted in a significantly higher production and
release of mediators such as histamine, LTC4/D4/E4 and
PGD2 compared to baseline, and these mediators were
released in a concentration-dependent manner.
Although we measured mediators which are relatively
restricted to mast cells such as histamine, PGD2 and LTC4/
D4/E4, we could not totally exclude that other cells, which
have been reported to express the IgE receptor, such as
dendritic cells [24] and eosinophils [25], may also have
been activated during this process. However, dendritic
cells do not produce and release histamine, LTC4/D4/E4 or
PGD2, and it is generally accepted that eosinophils are not
a source of histamine and PGD2. Moreover, it has been
shown that stimulation with human IgE and anti-IgE does
not cause production of leukotriene C4 in eosinophils
[26], demonstrating only mast cell activation in this set-
ting.
Theoretically, basophils could contribute to the responses
demonstrated here. It is, however difficult to discriminate
between basophils and mast cells as effector cells. There
are no reports about the number of basophils in nasal pol-
yps in literature, suggesting a minor role of those cells in
nasal polyps. Secondly, in the lamina propria of inferior
turbinates of allergic patients, at baseline, the number of
mast cells is at a median of 88%, with the percentages of
basophils being as low as 3%. Only after allergen provo-
cation, in the early phase, numbers of mast cells diminish
sharply to a median percentage of 27% and basophils
increase to 23% [27]. However, in the setting used here,
mast cells most probably are the major contributors, as an
influx of basophils in this ex-vivo model is impossible.
Moreover, studies measuring mediators in nasal lavage
fluid in an allergen-induced late-phase reaction revealed
high levels of histamine but relatively low levels of prod-
Figure 1
Histamine (ng/ml) (A), LTC4/D4/E4 (ng/ml) (B) and PGD2 (ng/ ml) (C) release after 30 minutes anti-IgE (10 μg/ml and 30 μg/ ml) stimulation Figure 1
Histamine (ng/ml) (A), LTC4/D4/E4 (ng/ml) (B) and 
PGD2 (ng/ml) (C) release after 30 minutes anti-IgE 
(10 μg/ml and 30 μg/ml) stimulation. Comparison 
between nasal polyps (n = 8) and inferior turbinates (n = 8) 
after correction for baseline. The box-and-whisker plot rep-
resents the median, the lower to upper quartile, and the min-
imum to the maximum value, excluding outside and far out 
values, which are displayed as separate points. Statistical anal-
yses were performed by using the Mann-Whitney U test. * p 
≤ 0.05, ** p ≤ 0.001. [Black line] = inferior turbinates, 
[Dashed line] = nasal polyps.Journal of Inflammation 2009, 6:11 http://www.journal-inflammation.com/content/6/1/11
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ucts such as PGD2. Since histamine is released by mast
cells and basophils, but prostaglandin D2 is not produced
by basophils, these findings have implicated the
basophils as an important contributor to histamine
release in the late phase but not in the early phase[28,29].
In the here presented model, we thus most likely restrict
the stimulation to mast cells.
Accessibility of nasal polyp tissue allows for easy assess-
ment of interaction between different cell types in an
inflammatory environment; however, the comparability
of results obtained from nasal polyp stimulations to infe-
rior turbinates was not studied so far. We therefore inves-
tigated the comparability of release of early mediators in
nasal polyps versus inferior turbinates. We here demon-
strate that the production and release of histamine, LTC4/
D4/E4 and PGD2 was significantly and consistently higher
in nasal polyps compared to inferior turbinates, both after
stimulation with anti-IgE 10 μg/ml and anti-IgE 30 μg/ml.
The increased release of early phase mast cell mediators in
nasal polyps could be due to the presence of a higher
number of mast cells in nasal polyps. However, no differ-
ence in the total number of tryptase-positive cells in infe-
rior turbinates compared to nasal polyps could be found
by tryptase staining. Literature reports show contradictory
findings; it is described that the number of epithelial mast
cells in nasal polyps is elevated compared to con-
trols[30,31] or that there is no difference in number of
epithelial mast cells compared to controls[17,32]. In line
with our findings, a recent study couldn't find any differ-
ence in the total number of mast cells between nasal pol-
yps and inferior turbinates[33].
It is well described that mast cells in nasal polyps are
mostly located in the stroma and are more degranulated
compared to inferior turbinate mast cells [34,35]. Further-
more, stromal mast cells of dispersed nasal polyp tissue
release higher amounts of histamine after anti-IgE stimu-
lation compared to epithelial mast cells of the same tis-
sue[36]. This underlines the heterogeneity of mast cells in
different tissues and could point to a more activated status
of polyp versus turbinate mast cells, and a higher sensitiv-
ity to external triggers. In line with our findings, levels of
mast cell-derived mediators such as histamine and tryp-
tase in nasal fluids from patients with nasal polyps are sig-
nificantly higher than those observed in patients without
nasal polyps [37]. Here we show that mast cells, even if
partially degranulated in polyp tissue, still can produce
and release higher amounts of mediators compared to the
non-degranulated mast cells in inferior turbinates.
Having shown that the number of mast cells present was
similar between polyp and turbinate tissue, we investi-
gated whether the number of FcεRIα-positive cells was dif-
ferent between the two tissue types, but no difference was
shown. The number of FcεRIα positive cells was higher
than the number of tryptase positive cells, in both nasal
polyps and inferior turbinates, which may be explained by
the staining of other than mast cells, such as basophils,
eosinophils [25] and dendritic cells [24].
Moreover, the FcεRIα chain expression at mRNA level did
not demonstrate any difference in relative expression in
nasal polyps compared to inferior turbinates. In the past,
our group and others have described significantly higher
levels of IgE in nasal polyp homogenates compared to
Numbers of tryptase positive cells (A) and FcεRIα positive cells (B) in the inferior turbinate group (Inf Turb) (n = 8) and the  nasal polyp group (NP) (n = 8), expressed as 10 scored fields (×400) Figure 2
Numbers of tryptase positive cells (A) and FcεRIα positive cells (B) in the inferior turbinate group (Inf Turb) (n 
= 8) and the nasal polyp group (NP) (n = 8), expressed as 10 scored fields (×400). The mRNA expression of FcεRIα 
in the inferior turbinate group and the nasal polyp group (C). The box-and-whisker plot represents the median, the lower to 
upper quartile, and the minimum to the maximum value, excluding outside and far out values, which are displayed as separate 
points. Statistical analyses were performed by using the Mann-Whitney U test. NS = Not Significant.Journal of Inflammation 2009, 6:11 http://www.journal-inflammation.com/content/6/1/11
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controls [17,38]. As IgE levels may control cell surface lev-
els of FcεRI [39], we expected higher levels of FcεRIα
mRNA in the nasal polyps, which then could explain the
increased release of mediators. However, in line with our
results, other studies demonstrated that the presence or
absence of IgE has no influence on the levels of mRNA for
either alpha, beta, or gamma subunits of FcεRI [40,41].
In cord blood derived human mast cells, pre-incubation
of mast cells for 4 days with IgE resulted in an enhance-
ment of the IgE-binding ability of cells, and this was
reflected by an increased surface expression of FcεRI.
Moreover, this resulted in the elevated release of hista-
mine, LTC4  and PGD2  in response to anti-IgE chal-
lenge[12]. However, we were not able to demonstrate a
correlation between baseline IgE levels in nasal polyp and
inferior turbinate homogenates and the amount of hista-
mine, LTC4/LTD4/LTE4 or PGD2 release upon stimulation.
Moreover, the release of mediators also was significantly
different in polyp versus turbinate tissue after ionomycin
stimulation, suggesting that the higher release in nasal
polyps might be unrelated to the surface expression of
FcεRI. Further studies need to clarify the mechanism
behind this phenomenon.
Conclusion
To conclude, a whole tissue nasal mucosal stimulation
model was established which can be used to mimic the
early phase of an allergic reaction both in nasal polyps
and inferior turbinates.
We observed a significantly higher release of mast cell
mediators after equivalent stimulation of nasal polyp tis-
sues compared to inferior turbinates, the mechanism of
which remains unclear. It is well recognized that mast
cells with distinct functional and histochemical properties
are present in human tissues [42,43]. The functional het-
erogeneity, the micro-environmental forces that dictate
Representative staining of tryptase positive cells in inferior turbinate tissue (A) and in nasal polyp tissue (B) Figure 3
Representative staining of tryptase positive cells in inferior turbinate tissue (A) and in nasal polyp tissue (B). 
Representative staining of FcεRIα positive cells in inferior turbinate tissue (C) and in nasal polyp tissue (D) (× 200).Journal of Inflammation 2009, 6:11 http://www.journal-inflammation.com/content/6/1/11
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responsiveness and the impact of disease on mast cell
response might be important in this process.
As high amounts of nasal polyp tissue are easier to access,
and as nasal polyps and inferior turbinate tissue react in
the same concentration- dependent manner to IgE-
dependent triggers, nasal polyp tissue could be used to
study the effect of inhibitors of the allergic early phase
reaction in future settings.
Abbreviations
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